Carl Schmidt joins WVU Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Carl Schmidt, a surgical oncologist specializing in cancers of the liver, pancreas, and stomach, will join the West Virginia University Cancer Institute in July.

Schmidt will serve chief of surgical oncology and surgeon in chief of the WVU Cancer Institute. He plans to grow the program’s capacity to serve a larger number of patients and offer more innovative surgeries through fostering relationships across the state.

Schmidt comes to WVU from the Ohio State University College of Medicine Wexner Medical Center, where he served as associate professor of surgery. At Ohio State, he also served as vice chair of quality and patient safety and program director for surgical oncology fellowships.

Schmidt’s scholarly work focuses on outcomes for patients with gastrointestinal cancers and quality of care for cancer patients.

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login